Re: an American-dream life story of Matt Emmens You're right that Genentech or Gilead are not realistic
comparisons for Vertex in the next few years. But
Vertex in 2012 could certainly look something like
Biogen did in 2007-2008. Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
Re: New offering!!!!!! They only said they had enough cash to take Telaprevir
to approval. They must need to ramp clinical trial
expense in a big way in 2010 for something else. Shall
we say 222? Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals (VRTX)
Re: Schering-Plough Yes, Disney! They can dress up Pamela Anderson like
Minnie Mouse and let her market Telaprevir. Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals (VRTX)
Re: WTF is wrong now with the share price To follow up on my prior post-- Galleon is listed (on
EDGAR Pro) as having a position of 60 thousand shares
in VRTX as of June 30th. Who knows what they may have
bought or... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals (VRTX)
Re: VRTX to sell rights to Hep C drug Two reasons to do this. First, by raising money in
this fashion the company could be telegraphing that
it won't use the recent improvement in stock price
as an opportunity to issue... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
Re: Comments after reading NEJM articles We won't have to wait until the Phase III results
to see some answers to the rash question. Study C208
is the open label Phase II dosing trial where we should
get a good... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
Re: That could the end of Schering HEP-C Note that this study from SGP is "open label"
compared to the VRTX phase II trials which were blind.
So, one could easily explain away the slightly "superior"
cure rate by... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
"Cure" for HCV you probably don&&39;t want Interesting study finds that acute case of HBV in a
patient with chronic HCV can lead to clearance of
HCV. There is a catch, however. You might die from
acute HBV and you only have a 25% of... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
Re: Forget JNJ..... I will take a stab. Genentech is already a profitable
company and is valued as such. Vertex, on the other
hand, has a valuation which only reflects the discounted
value of... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
Re: Current burn rate $$$ The "discrepency" is that their 9/30 financials
reported $920 million in liquidity whereas the more
recent press release indicated that the company ended
2008 with $830... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
Re: Current burn rate $$$ They actually said they ended 2008 with $830 million
of cash and also said they could have a non-GAAP loss
of up to $435 million in 2009. So, the ballpark answer
is that they will burn through 50... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
Re: up 2.07 DID YOU SEE THE CEO TODAY For the person who complained about the annual cost
of treatment, in case you haven't noticed VRTX
is losing nearly half a billion dollars per year primarily
to pay for the... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
Re: failed prior therapy Boger responded to a question about that topic in the
most recent earnings conference call. He said they
were "preserving the integrity" of the trials
for discussion with the... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
AASLD Abstract Data Available SVR of 67% (10 of 15 patients who completed combination
treatment) from long term follow up of phase 1b study
of telaprevir.This is one bit of info from one of
the abstracts available. Go to the... Business & Finance > Investments > Stocks (A to Z) > Stocks V > Vertex Pharmaceuticals Incorporated
